Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

Exclusion Criteria

• •a history of liver transplantation
• •with severe cirrhosis complications, including a history of esophagogastric variceal bleeding, hepatic encephalopathy, and massive ascites
• •with active autoimmune diseases or a history of autoimmune disease
• •with human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)
• •allergic to the ingredient of tislelizumab or regorafenib
• •with recurrent lesions treated with radiotherapy previously
• •prescribed radiation does could not be delivered due to dose limits to organs at risk (OAR)
• •intolerable to radiation or systemic treatment because of cardiac insufficiency, uncontrolled high blood pressure
• •a history of other malignancies, except cured basal cell or squamous cell skin cancer or carcinoma in situ of the cervix